Invesaro

Stocks Health care RPRX

NASDAQ · Health care

Royalty Pharma plc (RPRX)

Royalty Pharma plc brought in $2.5B of revenue over the twelve months to June 30, 2026, up 10.0% from a year earlier. Net income was $812M, a net margin of 32.0%. At June 30, 2026 it held $812M in cash against $9B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 5, 2026.

Price
$58.21
-0.14% on the day · September 25, 2026
52-week range $34.79 to $64.38
Market cap
$33.5B
Revenue (last 12 months)
$2.5B
+10.0% year on year
Net margin
32.0%
P/E
32.7
on FY2025 diluted EPS

What Royalty Pharma plc does

Royalty Pharma plc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker RPRX.

Revenue and profit by year

Revenue
FY18: $1.8B $1.8B FY18FY20: $1.8B $1.8B FY20FY20: $2.1B $2.1B FY20FY21: $2.3B $2.3B FY21FY22: $2.2B $2.2B FY22FY23: $2.4B $2.4B FY23FY24: $2.3B $2.3B FY24FY25: $2.4B $2.4B FY25
Net income
FY18: $1.4B $1.4B FY18FY20: $2.3B $2.3B FY20FY20: $975M $975M FY20FY21: $619.7M $619.7M FY21FY22: $42.8M $42.8M FY22FY23: $1.1B $1.1B FY23FY24: $859M $859M FY24FY25: $770.9M $770.9M FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$2.4B$1.6B$770.9M$1.78n/a
2024$2.3B$1.3B$859M$1.91n/a
2023$2.4B$1.5B$1.1B$2.53n/a
2022$2.2B$307.1M$42.8M$0.10n/a
2021$2.3B$1.4B$619.7M$1.49n/a
2020$2.1B$1.6B$975M$1.32n/a

Latest SEC filings

What Royalty Pharma plc has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. August 17, 2026
    Activist stake changed SCHEDULE 13D/A
  2. August 14, 2026
    Form 13F-NT filing 13F-NT
  3. August 5, 2026
    Quarterly report 10-Q · period to June 30, 2026
  4. August 5, 2026
    Quarterly results 8-K
  5. June 16, 2026
    Activist stake changed SCHEDULE 13D/A
  6. June 4, 2026
    Shareholder vote results 8-K
  7. May 28, 2026
    Material agreement 8-K
  8. May 14, 2026
    Form 13F-NT filing 13F-NT
  9. May 14, 2026
    Passive stake changed SCHEDULE 13G/A
  10. May 6, 2026
    Quarterly report 10-Q · period to March 31, 2026

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 24, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about RPRX

What does Royalty Pharma plc do?

Royalty Pharma plc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker RPRX.

Is Royalty Pharma plc profitable?

Yes. Over the twelve months to June 30, 2026 it reported net income of $812M on revenue of $2.5B, a net margin of 32.0%.

How much revenue does Royalty Pharma plc make?

Over the twelve months to June 30, 2026 Royalty Pharma plc reported revenue of $2.5B. That is 10.0% more than a year earlier.

When did Royalty Pharma plc last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 5, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 24, 2026.

Similar companies

JNJ
Johnson & Johnson
LLY
ELI LILLY & Co
MRK
Merck & Co., Inc.
PFE
Pfizer Inc
ABBV
AbbVie Inc.
AZN
Astrazeneca PLC

Follow RPRX

Get an email when Royalty Pharma plc files with the SEC: results, executive changes, material agreements and annual reports.

Follow RPRX: get an email when it files

Where the numbers come from

Financial figures are the values Royalty Pharma plc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.